Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

81. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis

The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis Menees SB, Maneerattannaporn M, Kim HM, Chey WD CRD summary The authors concluded that treatment with rifaximin was more effective than placebo for global symptoms (...) and bloating in patients with irritable bowel syndrome. The modest therapeutic gain was similar to that of other therapies. The authors' conclusion for short-term treatment compared with placebo reflects the evidence presented and seems reliable; the comparison with other treatments is not substantiated. Authors' objectives To evaluate the efficacy and tolerability of rifaximin in patients with irritable bowel syndrome (IBS). Searching PubMed, EMBASE, The Cochrane Library and Web of Science were searched up

2012 DARE.

82. Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care (Full text)

Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised (...) with irritable bowel syndrome (IBS). The authors concluded that acupuncture was not cost-effective for all patients, but it might be for a subgroup of patients with more severe disease. The methods and data used for the analysis were clearly reported and appropriate. The authors' conclusion appears to be appropriate. Type of economic evaluation Cost-utility analysis Study objective This study evaluated the cost-effectiveness of acupuncture for patients with irritable bowel syndrome (IBS). Interventions

2012 NHS Economic Evaluation Database. PubMed

83. Systematic review with meta-analysis: In irritable bowel syndrome, antispasmodics and antidepressants improve abdominal pain and global assessment and symptom scores, but there is no evidence for the effectiveness of bulking agents

Systematic review with meta-analysis: In irritable bowel syndrome, antispasmodics and antidepressants improve abdominal pain and global assessment and symptom scores, but there is no evidence for the effectiveness of bulking agents In irritable bowel syndrome, antispasmodics and antidepressants improve abdominal pain and global assessment and symptom scores, but there is no evidence for the effectiveness of bulking agents | BMJ Evidence-Based Medicine We use cookies to improve our service (...) name or password? You are here In irritable bowel syndrome, antispasmodics and antidepressants improve abdominal pain and global assessment and symptom scores, but there is no evidence for the effectiveness of bulking agents Article Text This article has a correction. Please see: Therapeutics Systematic review with meta-analysis In irritable bowel syndrome, antispasmodics and antidepressants improve abdominal pain and global assessment and symptom scores, but there is no evidence

2012 Evidence-Based Medicine (Requires free registration)

84. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation (PubMed)

Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation Linaclotide, a minimally absorbed, 14-amino acid peptide agonist of guanylate cyclase-C, has shown benefit in a proof-of-concept study for the treatment of patients with irritable bowel syndrome (IBS) with constipation (IBS-C). We assessed the efficacy and safety of linaclotide at a daily dose range of 75-600 μg in IBS-C.We performed a randomized, double-blind (...) , multicenter, placebo-controlled study of 420 patients with IBS-C given oral linaclotide at doses of 75, 150, 300, or 600 μg or placebo once daily for 12 weeks. End points included change from baseline in daily bowel habits, daily abdominal symptoms, and weekly global assessments, in addition to responder criteria.All doses of linaclotide significantly improved bowel habits, including frequency of spontaneous bowel movements and complete spontaneous bowel movements (primary end point), severity

2011 EvidenceUpdates

85. Irritable bowel syndrome immune hypothesis. Part two: the role of cytokines.

Irritable bowel syndrome immune hypothesis. Part two: the role of cytokines. To review the available evidence on the role of interleukins in the etiopathogenesis of Irritable Bowel Syndrome.Bibliographic retrieval on PubMed including the MeSH terms "Irritable Bowel Syndrome, "Immune System", "Cytokines" and "Interleukins".Sixteen case-control studies and one randomised controlled trial were retrieved. The blood appears to have a high concentration of pro-inflammatory cytokines (TNF- á , IL-1 â

2011 Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva

86. Rifaximin therapy for patients with irritable bowel syndrome without constipation. (PubMed)

Rifaximin therapy for patients with irritable bowel syndrome without constipation. Evidence suggests that gut flora may play an important role in the pathophysiology of the irritable bowel syndrome (IBS). We evaluated rifaximin, a minimally absorbed antibiotic, as treatment for IBS.In two identically designed, phase 3, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2), patients who had IBS without constipation were randomly assigned to either rifaximin at a dose of 550 mg

2011 NEJM

87. Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis (Full text)

Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis Sodium chenodeoxycholate (CDC) accelerates colonic transit in health. Our aim was to examine pharmacodynamics (colonic transit, bowel function) and pharmacogenetics of CDC in constipation-predominant irritable bowel syndrome (IBS-C).In a double-blind placebo-controlled study, 36 female patients with IBS-C were randomized to treatment with delayed-release oral formulations (...) variation in FGFR4 was associated with AC t(½) in response to CDC (uncorrected P = .015); αKlothoβ variant showed a gene-by-treatment interaction based on patient subgroup (uncorrected P = .0088).CDC accelerates colonic transit and improves bowel function in female patients with IBS-C. The rate of bile acid synthesis influences colonic transit. Genetic variation in negative feedback inhibition of bile acid synthesis may affect CDC-mediated acceleration of colonic transit.Copyright © 2010 AGA Institute

2010 EvidenceUpdates PubMed

88. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review (PubMed)

The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review Probiotics may benefit irritable bowel syndrome (IBS) symptoms, but randomised controlled trials (RCTs) have been conflicting; therefore a systematic review was conducted.MEDLINE (1966 to May 2008), EMBASE (1988 to May 2008) and the Cochrane Controlled Trials Register (2008) electronic databases were searched, as were abstracts from DDW (Digestive Diseases Week) and UEGW (United European

2010 EvidenceUpdates

89. A randomized, double-blind, placebo-controlled trial of St John`s wort for treating irritable bowel syndrome (PubMed)

A randomized, double-blind, placebo-controlled trial of St John`s wort for treating irritable bowel syndrome St John's wort (SJW) is known to effectively treat patients with mild-to-moderate depression. Antidepressants are frequently used to treat irritable bowel syndrome (IBS). To date, no study that examines the efficacy of SJW in IBS has been carried out. The aim of this study was to evaluate the efficacy of SJW in IBS after 12 weeks.In this randomized, double-blind, placebo-controlled trial (...) , 70 participants with an established diagnosis of IBS were randomized and assigned by concealed allocation to either SJW or placebo. Both treatment arms were balanced on symptom subtype. The primary end point was self-reported overall bowel symptom score (BSS) at 12 weeks. Secondary end points were individual BSS for diarrhea (D-BSS), constipation (C-BSS), pain or discomfort, and bloating; adequate relief (AR) of IBS on at least 50% of the last 4 weeks of therapy; and IBS quality-of-life score

2010 EvidenceUpdates

90. [Burden of irritable bowel syndrome in Korea]

[Burden of irritable bowel syndrome in Korea] [Burden of irritable bowel syndrome in Korea] [Burden of irritable bowel syndrome in Korea] Choi MG, Jung HK, Jang BH, Kim Y, Nam MH, Park SY, Park J, Park HJ, Lee PL, Lee JS, Lee KJ Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Choi MG, Jung HK, Jang BH, Kim Y, Nam MH, Park SY, Park J, Park (...) HJ, Lee PL, Lee JS, Lee KJ. [Burden of irritable bowel syndrome in Korea] Seoul: National Evidence-based Healthcare Collaborating Agency (NECA). NECA-A-09-018, NECA-A-10-007. 2010 Authors' conclusions During a single year of 2008, the prevalence of IBS was 5.1% in males and 6.9% in females, yielding a female/male ratio of 1.44. According to the survey, the estimation of patients' quality of life by using the EQ-5D tool resulted in a score of 0.889 that was lower than the score (EQ-5D index

2010 Health Technology Assessment (HTA) Database.

91. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome (Full text)

A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome Darvish-Damavandi M, Nikfar S, Abdollahi M CRD summary The review concluded that mebeverine did not significantly improve the global symptoms of irritable bowel syndrome or relieve the associated abdominal pain (...) , but it was mostly well tolerated, with no significant adverse events. Although the included trials were of high quality, the evidence was limited, so the reliability of the authors' conclusions is unclear. Authors' objectives To evaluate the safety and efficacy of mebeverine for irritable bowel syndrome. Searching PubMed, EMBASE, Scopus, and the Cochrane Library were searched up to June 2009 for publications in any language; search terms were reported. Google was also searched. Bibliographies of each retrieved

2010 DARE. PubMed

92. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review

The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM CRD summary This review concluded that probiotics appeared to be efficacious in the treatment of irritable bowel syndrome (...) , but that the magnitude of benefit and the most effective probiotic species and strain remained uncertain. The review was generally well conducted and the authors' conclusions are likely to be reliable. Authors' objectives To assess the efficacy of probiotics in the treatment of irritable bowel syndrome. Searching The following databases were searched, with no language restrictions, from inception to June 2008: MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials. Search terms were reported

2010 DARE.

93. Comprehensive self-management for irritable bowel syndrome: randomized trial of in-person vs. combined in-person and telephone sessions (Full text)

Comprehensive self-management for irritable bowel syndrome: randomized trial of in-person vs. combined in-person and telephone sessions Psychological and behavioral therapies are being increasingly used for symptom management in patients with irritable bowel syndrome (IBS). The aims of this study were to compare two delivery modes for a comprehensive self-management (CSM) intervention, primarily by telephone vs. entirely in person, and to compare each with usual care (UC).Adults with IBS were

2010 EvidenceUpdates PubMed

94. Systematic review: self-management support interventions for irritable bowel syndrome

Systematic review: self-management support interventions for irritable bowel syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

95. The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis

The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

96. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof of concept study (Full text)

Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof of concept study Intestinal immune infiltration contributes to symptoms in patients with irritable bowel syndrome (IBS).To assesses the effect of mesalazine (mesalamine) on mucosal immune cells in patients with IBS, through a pilot study.A randomized, double-blind, placebo-controlled trial in 20 patients with IBS in tertiary care setting. Patients were randomized to receive placebo (...) ). Mesalazine significantly increased general well-being (P = 0.038), but had no significant effects on abdominal pain (P = 0.084), bloating (P = 0.177) or bowel habits. No serious drug-related adverse events were reported during the study.Mesalazine is an effective and safe approach to reduce mast cell infiltration and may improve general well-being in patients with IBS. These results support the hypothesis that immune mechanisms represent potential therapeutic targets in IBS.

2009 EvidenceUpdates PubMed

97. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis (PubMed)

Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis Irritable bowel syndrome (IBS) is a chronic functional disorder. 5-Hydroxytryptamine (5-HT) is a key modulator of gastrointestinal sensorimotor function. Many patients have IBS that can be difficult to treat, which has led to the development of newer agents, such as 5-HT(3) antagonists and 5-HT(4) agonists. We conducted a systematic review and meta-analysis of randomized controlled

2009 EvidenceUpdates

98. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis (PubMed)

Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder. Evidence for treatment of the condition with antidepressants and psychological therapies is conflicting.Systematic review and meta-analysis of randomised controlled trials (RCTs). MEDLINE, EMBASE and the Cochrane Controlled Trials Register were searched (up to May 2008).RCTs based in primary

2009 EvidenceUpdates

99. Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. (PubMed)

Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Between 4% and 25% of school-age children complain of recurrent abdominal pain (RAP) of sufficient severity to interfere with daily activities. It is unclear whether the diagnosis includes children with different aetiologies for their pain. For the majority no organic cause for their pain can be found on physical examination or investigation. Although most children are likely managed

2009 Cochrane

100. Psychological treatments for the management of irritable bowel syndrome. (PubMed)

Psychological treatments for the management of irritable bowel syndrome. No consensus exists on the optimal treatment for irritable bowel syndrome (IBS). Psychological treatments are increasingly advocated but their effectiveness is unclear.To evaluate the efficacy of psychological interventions for the treatment of irritable bowel syndrome.A computer assisted search of MEDLINE, EMBASE, PsychInfo, CINAHL, Web of Science, The Cochrane Library and Google Scholar was performed for the years 1966

2009 Cochrane